XtalPi, an American-Chinese AI drug discovery company backed by Google, has raised USD 400 million in a Series D funding round led by OrbiMed and RRJ. Investors including Sequoia Capital, Sino Biopharmecutical, and 5Y Capital also participated in the round.
The company’s value reached RMB 13 billion (USD 2 billion) and reportedly comes ahead of a potential initial public offering (IPO) expected in the coming quarters. The latest financing surpassed its last Series C funding round of September 2020 in which XtalPi raised USD 319 million.
The proceeds will be directed towards the company’s expansion plans and explore a number of verticals within drug development.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.